Vistin Pharma (VISTIN)

pleximus83 · mars 31, 2020, 9:31am

ok…etter kapitalinnhentingen ved siste emisjon vedrørende Energisatsingen til Vistin,så utestår det nå en del aksjer som jeg mener kan utvanne den kommende overskudds effekten pr . aksje…

Vistin hadde engang ca. 17 000 000 aksjer,og har idag 44 344 592 aksjer utestående.

grovt regnet,ser jeg for meg ca. 0,45 netto resultat pr aksje på kort sikt,og 0,90 pr. aksje på lang sikt(etter dobbling av kapasiteten).

rayman · mars 31, 2020, 9:45am

Stemmer, dette var jeg klar over da jeg kjøpte

De har pratet om å øke produksjonen i flere år, men det skjer jo ikke noe. Vet noen hva som er grunnen til det?

rayman · april 2, 2020, 4:46am

TekBot · april 20, 2020, 6:15am

Vistin Pharma ASA: Invitation to Q1 2020 conference call

Oslo, Norway, 20 April 2020

Vistin Pharma ASA will release its first quarter 2020 results on
…
Vis børsmeldingen

Thursday 23 April 2020. Vistin Pharma will host a conference call for all
shareholders and interested parties on Thursday 23 April at 08:30 CET. There
will be a Q&A session following the management discussion.

The conference call will be held in Norwegian.

The first quarter conference call will be available via web and audio through
the following access points:

Telephone conference:
Confirmation Code:… 5385809
International Dial-In:… +44 (0) 2071 928000
Norway, Oslo:… +47 23960264
United States, New York: +16315107495

Webcast:
https://edge.media-server.com/mmc/p/za9hkqym
                                 *****
For further information, please contact:

Alexander Karlsen
CFO
+47 97053621
alexander.karlsen@vistin.com (mailto:alexander.karlsen@vistin.com)

About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin
Hydrochloride (API). The Metformin is also available as Direct Compressible
lubricated granules. As a solely dedicated European Metformin producer, Vistin
Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin
Pharma is headquartered in Oslo, Norway, and has highly qualified employees and
a dedicated manufacturing facility in Kragerø.

Kilde

TekBot · april 23, 2020, 5:59am

Vistin Pharma ASA: First quarter 2020 financial results

Oslo, Norway, 23 April 2020

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial
…
Vis børsmeldingen

results for the first quarter of 2020, with a 45% increase in revenue and a
record quarterly result of 14.2 million for the pharmaceutical business.

As previously announced all oil derivate positions in the Energy trading
business was closed on the 30(th) of March. The net financial loss in Q1 from
closing the portfolio was approx. NOK 166 million.

The revenues for the first quarter 2020 ended at NOK 61.4 million (Q1 2019: NOK
42.2 million).

The net loss for the period ended at NOK 130.8 million (2.0), which included the
loss of closing the oil derivative portfolio.

Vistin Pharma had cash of NOK 316.8 million (299.6) as of 31 March 2020.
Settlement for oil derivatives was not completed before April (Q2). The
settlement will decrease the above cash balance with approx. NOK 179M.

Based on the closing and final settlement of the oil derivative positions, the
Board will propose to pay a dividend of NOK 1 per share to its shareholders. The
dividend to be approved by the AGM.

The first quarter conference call, which will be held today, 23 April, at
8.30am (CEST) and will be available via web and audio through the following
access points:

Telephone conference:
Confirmation Code:… 5385809
International Dial-In:… +44 (0) 2071 928000
Norway, Oslo:… +47 23960264
United States, New York: +16315107495

Webcast:
https://edge.media-server.com/mmc/p/za9hkqym

The conference call will be held in Norwegian.

Please find the Q1 2020 Report and presentation enclosed. The report will also
be made available on www.vistin.com (http://www.vistin.com).
                                 *****
For further information, please contact:

Kjell-Erik Nordby
CEO
+47 91 36 42 80
kjell-erik.nordby@vistin.com (mailto:kjell-erik.nordby@vistin.com)

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com (mailto:alexander.karlsen@vistin.com)

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin
Hydrochloride (API). The Metformin is also available as Direct Compressible
lubricated granules. As a solely dedicated European Metformin producer, Vistin
Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin
Pharma is headquartered in Oslo, Norway, and has highly qualified employees and
a dedicated manufacturing facility in Kragerø.

Kilde

TekBot · april 23, 2020, 5:59am

Vistin Pharma ASA: Expansion of the metformin manufacturing capacity

Oslo, Norway, 23 April 2020

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN), announces that the Board of
…
Vis børsmeldingen

Directors have approved the investment to install a 2(nd) production line and
double the production capacity to approx. 7000MT at its dedicated metformin
manufacturing facility at Fikkjebakke, Kragerø.

The expansion is driven by a stable underlying growth in the metformin market,
and that the demand from the existing customers will exceed Vistin’s
manufacturing capacity going forward.

The investment will be approximately NOK 100 million and will be financed
through existing cash balance and running cash flow. Commercial volumes from the
new production line is expected to be available in 2022.

This expansion is an important milestone in the company’s ambition to further
strengthen its position as one of the leading global metformin producers says
Kjell-Erik Nordby, CEO in Vistin Pharma.
                                 *****
For further information, please contact:

Kjell-Erik Nordby
CEO
+47 91 36 42 80
kjell-erik.nordby@vistin.com (mailto:kjell-erik.nordby@vistin.com)

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com (mailto:alexander.karlsen@vistin.com)

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin
Hydrochloride (API). The Metformin is also available as Direct Compressible
lubricated granules. As a solely dedicated European Metformin producer, Vistin
Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin
Pharma is headquartered in Oslo, Norway, and has highly qualified employees and
a dedicated manufacturing facility in Kragerø.

Kilde

ole-johan86 · april 26, 2020, 9:37am

Rart at dette ikke er børsmeldt.

Kjell_Makrell · april 26, 2020, 10:10am

Vært heldig med Vistin så langt. 44 % stigning og utbytte på aksjene

Storg · april 26, 2020, 10:16am

Det er jo børsmeldt.

rayman · april 26, 2020, 10:22am

Det ble nevnt i forrige rapport, du finner det på newsweb

ole-johan86 · april 26, 2020, 11:21am

Takker! Her har jeg fulgt med for dårlig tydeligvis.

TekBot · april 28, 2020, 2:02pm

Vistin Pharma ASA : Call for annual general meeting

Oslo, Norway, 28 April 2020

Vistin Pharma ASA (OSE: VISTIN), please find attached the call for the Annual
…

Vis børsmeldingen

General Meeting in Vistin Pharma, to be held on 19 May at 13:00 CEST. Due to
the Covid-19 situation, the Annual General Meeting will be held as a digital
meeting. Information with guide for online participation will be shared in well
advance of the general meeting. The recommendation from the Election Committee
will be made available on the Company’s website as soon as it has been
finalised. The formal call will be sent to all shareholders registered in the
Norwegian Central Security Depository (VPS).

The complete set of documents relating to the annual general meeting will be
made available on www.vistin.com.

For further information, please contact:

Alexander Karlsen

CFO

+47 97 05 36 21

alexander.karlsen@vistin.com (mailto:alexander.karlsen@vistin.com)

This information is subject to the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

Kilde

Kjell_Makrell · april 28, 2020, 9:32pm

Så utbytte som ble bestemt her forrige uke kommer først 7 juni?

Kjell_Makrell · april 30, 2020, 5:11am

Takk for svar

TekBot · mai 5, 2020, 10:41am

CORRECTION: Vistin Pharma ASA : Key information relating to the cash dividend to be paid by Vistin Pharma ASA

TekBot · mai 5, 2020, 2:37pm

Flaggemelding - VISTIN PHARMA AS

TekBot · mai 12, 2020, 11:02am

Vistin Pharma ASA: Guide for online participation at AGM

Oslo, Norway, 12 May 2020

Vistin Pharma ASA (OSE: VISTIN), as previously announced Vistin Pharma ASA will
…

Vis børsmeldingen

be conducting this year’s Annual General Meeting on the 19 of May as a digital
meeting, through Skype. This is a precautionary measure to prevent the spread of
Covid-19 and to ensure the safety and wellbeing of our shareholders, employees
and other stakeholders. Therefore, there will be no opportunity for physical
presence this year. You may cast votes prior to the meeting or grant a proxy as
in previous years. Please refer the notice for the AGM and appendices for
further information on voting in advance and proxies. Attached is a stepwise
guide for how to attend the meeting.

The complete set of documents relating to the Annual General Meeting are
available on www.vistin.com (http://www.vistin.com)

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com (mailto:alexander.karlsen@vistin.com)

This information is subject to the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mai 19, 2020, 1:15pm

Vistin Pharma ASA: Minutes from the Annual General Meeting 2020

TekBot · mai 19, 2020, 1:48pm

Vistin Pharma ASA - aksjekjøp

TekBot · mai 19, 2020, 1:58pm